keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/29151113/cpne1-is-a-useful-prognostic-marker-and-is-associated-with-tnf-receptor-associated-factor-2-traf2-expression-in-prostate-cancer
#1
Jiabei Liang, Jian Zhang, Jun Ruan, Yuanyuan Mi, Qiang Hu, Zhirong Wang, Bingbing Wei
BACKGROUND CPNE1 plays a vital role in regulating cell differentiation. The clinical and biological values of CPNE1 in prostate cancer are still unclear. The aim of this study was to investigate the clinicopathological value of CPNE1 and the association of CPNE1 with TRAF2 expression in patients with prostate cancer. MATERIAL AND METHODS CPNE1 expression in prostate cancer was analyzed using Gene Expression Omnibus (GEO) databases. The Cancer Genome Atlas (TCGA) dataset was used to investigate the association of CPNE1 expression with TRAF2 expression in prostate cancer...
November 19, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/29149993/label-free-determination-of-prostate-specific-membrane-antigen-in-human-whole-blood-at-nanomolar-levels-by-magnetically-assisted-surface-enhanced-raman-spectroscopy
#2
Zuzana Chaloupková, Anna Balzerová, Jitka Bařinková, Zdenka Medříková, Pavel Šácha, Petr Beneš, Václav Ranc, Jan Konvalinka, Radek Zbořil
Prostate cancer is one of the most common cancers among men and can in its later stages cause serious medical problems. Due to the limited suitability of current diagnostic biochemical markers, new biomarkers for the detection of prostate cancer are highly sought after. An ideal biomarker should serve as a reliable prognostic marker, be applicable for early diagnosis, and be applicable for monitoring of therapeutic response. One potential candidate is glutamate carboxypeptidase II (GCPII), also known as prostate specific membrane antigen (PSMA), which has a promising role for direct imaging...
January 2, 2018: Analytica Chimica Acta
https://www.readbyqxmd.com/read/29141848/myc-overexpression-at-the-protein-and-mrna-level-and-cancer-outcomes-among-men-treated-with-radical-prostatectomy-for-prostate-cancer
#3
Andreas Pettersson, Travis Gerke, Kathryn L Penney, Rosina T Lis, Edward C Stack, Nelma Pértega-Gomes, Giorgia Zadra, Svitlana Tyekucheva, Edward L Giovannucci, Lorelei A Mucci, Massimo Loda
BACKGROUND: The proto-oncogene MYC is implicated in prostate cancer progression. Whether MYC tumor expression at the protein or mRNA level is associated with poorer prognosis has not been well studied. METHODS: We conducted a cohort study including 634 men from the Physicians' Health Study and Health Professionals Follow-up Study treated with radical prostatectomy for prostate cancer in 1983-2004 and followed-up for a median of 13.7 years. MYC protein expression was evaluated using immunohistochemistry, and we used Cox regression to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of its association with lethal prostate cancer (distant metastases/prostate cancer death)...
November 15, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/29141018/evaluation-of-the-proliferation-marker-ki-67-in-a-large-prostatectomy-cohort
#4
Elin Richardsen, Sigve Andersen, Samer Al-Saad, Mehrdad Rakaee, Yngve Nordby, Mona Irene Pedersen, Nora Ness, Thea Grindstad, Ingeborg Movik, Tom Dønnem, Roy Bremnes, Lill-Tove Busund
The tumor proliferation index marker Ki-67 is strongly associated with tumor cell proliferation, growth and progression, and is widely used in routine clinicopathological investigation. Prostate cancer is a complex multifaceted and biologically heterogeneous disease, and overtreatment of localized, low volume indolent tumors, is evident. Here, we aimed to assess Ki-67 expression and related outcomes of 535 patients treated with radical prostatectomy. The percentage of tumor epithelial cells expressing Ki-67 was determined by immunohistochemical assay, both digital image analysis and visual scoring by light microscope were used for quantification...
2017: PloS One
https://www.readbyqxmd.com/read/29137340/prognostic-role-of-tumour-associated-macrophages-and-macrophage-scavenger-receptor-1-in-prostate-cancer-a-systematic-review-and-meta-analysis
#5
Jian Cao, Jun Liu, Ran Xu, Xuan Zhu, Xiaokun Zhao, Bin-Zhi Qian
Recent studies suggested that the tumour associated macrophages may be associated with prostate cancer outcome. A meta-analysis was performed to evaluate the prognostic value of tumor associated macrophages and macrophage scavenger receptor 1, marker for a subset of macrophages, by pooled hazard ratio and 95% confidence intervals from qualified studies following a systemic search. The results indicate that higher infiltration of tumor associated macrophages predicts poor overall survival (HR=1.57, 95%CI: 1...
October 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29132337/gene-expression-signatures-of-neuroendocrine-prostate-cancer-and-primary-small-cell-prostatic-carcinoma
#6
Harrison K Tsai, Jonathan Lehrer, Mohammed Alshalalfa, Nicholas Erho, Elai Davicioni, Tamara L Lotan
BACKGROUND: Neuroendocrine prostate cancer (NEPC) may be rising in prevalence as patients with advanced prostate cancer potentially develop resistance to contemporary anti-androgen treatment through a neuroendocrine phenotype. While prior studies comparing NEPC and prostatic adenocarcinoma have identified important candidates for targeted therapy, most have relied on few NEPC patients due to disease rarity, resulting in thousands of differentially expressed genes collectively and offering an opportunity for meta-analysis...
November 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29129073/stage-dependence-cell-origin-independence-and-prognostic-capacity-of-serum-glycan-fucosylation-%C3%AE-1-4-branching-%C3%AE-1-6-branching-and-%C3%AE-2-6-sialylation-in-cancer
#7
Shadi Ferdosi, Douglas S Rehder, Paul Maranian, Erik P Castle, Thai H Ho, Harvey I Pass, Daniel W Cramer, Karen S Anderson, Lei Fu, David E C Cole, Tao Le, Xifeng Wu, Chad R Borges
Glycans represent a promising but only marginally accessed source of cancer markers. We previously reported the development of a molecularly bottom-up approach to plasma and serum (P/S) glycomics based on glycan linkage analysis that captures features such as α2-6 sialylation, β1-6 branching, and core fucosylation as single analytical signals. Based on the behavior of P/S glycans established to date, we hypothesized that the alteration of P/S glycans observed in cancer would be independent of the tissue in which the tumor originated yet exhibit stage dependence that varied little between cancers classified on the basis of tumor origin...
November 21, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/29122400/aberrant-promoter-methylation-of-the-paqr3-gene-is-associated-with-prostate-cancer
#8
Kowit Lounglaithong, Andrey Bychkov, Pichet Sampatanukul
Methylation markers are promising tools for diagnosis, prognosis and targeted treatment of cancer. In prostate carcinoma, aberrant promoter hypermethylation occurs earlier in the disease course and more consistently than recurrent somatic mutations. PAQR3, a tumor suppressor gene, was recently found to be downregulated in prostate cancer cell lines. We hypothesized that promoter methylation could be responsible for PAQR3 silencing in prostate cancer tissues. We aimed to investigate PAQR3 promoter methylation in prostate cancer by comparing it to benign prostatic hyperplasia (BPH)...
October 10, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29104488/cancer-stem-cell-gene-variants-predict-disease-recurrence-in-patients-treated-with-radical-prostatectomy-for-prostate-cancer
#9
Victor C Lin, Shu-Pin Huang, Chao-Yuan Huang, Chia-Cheng Yu, Hsin-Ling Yin, Tsung-Yi Huang, Cheng-Hsueh Lee, Te-Ling Lu, Bo-Ying Bao
Background: Cancer stem cells (CSCs) are involved in tumor progression and drug resistance. We hypothesized that variants in CSC marker genes influence treatment outcomes in prostate cancer. Methods: Ten potentially functional single nucleotide polymorphisms (SNPs) in seven prostate CSC marker genes, TACSTD2, PROM1, ITGA2, POU5F1, EZH2, PSCA, and CD44, were selected for analysis of their association with disease recurrence by Kaplan-Meier analysis and Cox regression in a cohort of 320 patients with localized prostate cancer receiving radical prostatectomy...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29104483/overexpression-of-endothelial-cell-specific-molecule-1-correlates-with-gleason-score-and-expression-of-androgen-receptor-in-prostate-carcinoma
#10
Chung-Yu Lai, Chien-Min Chen, Wen-Hung Hsu, Yi-Hsien Hsieh, Chung-Jung Liu
Endothelial cell-specific molecule 1 (ESM1) is a major prognostic marker of several tumor types, but its value as a marker for prostate cancer is unknown. The purpose of the present study was to measure the relationship of ESM1 expression with androgen receptor (AR) expression and with Gleason score in human prostate carcinoma tissue. Expression of ESM1 and AR were determined by immunohistochemical staining of prostate tissues from healthy individuals and patients with prostate cancer. The results showed that ESM1 expression was significantly higher in prostate tumor tissues than in normal prostate tissues (p < 0...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29094384/prognostic-parameter-for-high-risk-prostate-cancer-patients-at-initial-presentation
#11
Masashi Kato, Kyosuke Kimura, Akihiro Hirakawa, Yumiko Kobayashi, Ryo Ishida, Osamu Kamihira, Tsuyoshi Majima, Yasuhito Funahashi, Naoto Sassa, Yoshihisa Matsukawa, Ryohei Hattori, Momokazu Gotoh, Toyonori Tsuzuki
BACKGROUND: High-risk prostate cancer can be defined by a patient's Gleason score (GS), prostate-specific antigen (PSA) level, and clinical T (cT) stage, but a novel marker is needed due to heterogeneity of the disease. In this study, we evaluated whether intraductal carcinoma of the prostate (IDC-P) confirmed by needle biopsy is an adverse prognostic parameter for progression-free survival (PFS) and cancer-specific survival (CSS) in patients with high-risk prostate cancer. METHODS: We retrospectively evaluated 204 patients with high-risk prostate cancer treated by radical prostatectomy from 1991 to 2005 at Nagoya University and its affiliated hospitals...
November 2, 2017: Prostate
https://www.readbyqxmd.com/read/29073272/highly-aggressive-rat-prostate-tumors-rapidly-precondition-regional-lymph-nodes-for-subsequent-metastatic-growth
#12
Kerstin Strömvall, Marie Lundholm, Elin Thysell, Anders Bergh, Sofia Halin Bergström
The aim of this study was to examine in what ways MatLyLu (MLL) rat prostate tumors with high metastatic capacity influence regional lymph nodes prior to metastatic establishment compared to AT1 rat prostate tumors with low metastatic potential. MLL or AT1 tumor cells were injected into the ventral prostate of immunocompetent rats. Tumor and lymph node morphology, and lymph node mRNA expression of macrophage associated markers, T-cell associated markers, and cytokines were examined over time until the first microscopic signs of metastases (at day 14 for MLL- and at day 28 for AT1-tumors)...
2017: PloS One
https://www.readbyqxmd.com/read/29073199/reduced-expression-of-iqgap2-and-higher-expression-of-iqgap3-correlates-with-poor-prognosis-in-cancers
#13
Dinesh Kumar, Md Khurshidul Hassan, Niharika Pattnaik, Nachiketa Mohapatra, Manjusha Dixit
IQGAPs is a family of proteins which comprises three members, in humans. The expression pattern and role of IQGAP1 has been well established in many cancers, whereas those of IQGAP2 and IQGAP3, have mostly remained unexplored. We used available large datasets, to explore the pan-cancer status of these two genes in-silico. Here we have analysed their mRNA expression and correlation with survivability in eight different cancers, including lung, breast, gastric, brain, colorectal, prostate, liver and kidney cancers and, their subtypes...
2017: PloS One
https://www.readbyqxmd.com/read/29050357/oncomir-17-5p-alarm-signal-in-cancer
#14
REVIEW
Madhusudhan Reddy Bobbili, Robert M Mader, Johannes Grillari, Hanna Dellago
Soon after microRNAs entered the stage as novel regulators of gene expression, they were found to regulate -and to be regulated by- the development, progression and aggressiveness of virtually all human types of cancer. Therefore, miRNAs in general harbor a huge potential as diagnostic and prognostic markers as well as potential therapeutic targets in cancer. The miR-17-92 cluster was found to be overexpressed in many human cancers and to promote unrestrained cell growth, and has therefore been termed onco-miR-1...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29050295/a-comprehensive-study-of-circulating-tumour-cells-at-the-moment-of-prostate-cancer-diagnosis-biological-and-clinical-implications-of-egfr-ar-and-snps
#15
Ignacio Puche-Sanz, María J Alvarez-Cubero, Manrique Pascual-Geler, Alba Rodríguez-Martínez, Miguel Delgado-Rodríguez, José L García-Puche, José Expósito, Inmaculada Robles-Fernández, Carmen Entrala-Bernal, José A Lorente, José M Cózar-Olmo, María J Serrano
Circulating tumor cells (CTCs) have been recently accepted as prognostic markers in metastatic prostate cancer (PCa). However, very few studies have analyzed their role in early-stage PCa. The aim of this research is to study the value of CTCs at the moment of PCa diagnosis and to identify different subpopulations of CTCs. Patients with PSA value > 4 ng/ml and clinical suspicion of PCa were included. Samples were collected immediately before prostatic biopsy. CTCs were isolated by immunomagnetic technique using a multi-CK specific antibody...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29026066/aberrant-promoter-methylation-of-protocadherin8-pcdh8-in-serum-is-a-potential-prognostic-marker-for-low-gleason-score-prostate-cancer
#16
Ying-Li Lin, Yan-Li Li, Jian-Guo Ma
BACKGROUND PCDH8 is a newly-discovered suppressor gene that is frequently inactivated by aberrant methylation in several human cancers, including prostate cancer. The identification of PCDH8 methylation can be used as a potential predictive biomarker. Prostate cancer patients with high Gleason score are considered as being at high risk for tumor recurrence and progression, and adjuvant therapy is often routinely performed in clinical practice. In the present study, we did not measure the methylation of PCDH8 in these patients...
October 13, 2017: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/28993510/genomic-gain-of-16p13-3-in-prostate-cancer-predicts-poor-clinical-outcome-after-surgical-intervention
#17
Yogesh M Bramhecha, Karl-Philippe Guérard, Shaghayegh Rouzbeh, Eleonora M Scarlata, Fadi Brimo, Simone M A Chevalier, Lucie Hamel, Alice Dragomir, Armen Aprikian, Jacques Lapointe
Identifying tumors with high metastatic potential is key to improving the clinical management of prostate cancer (PCa). Recently, we characterized a chromosome 16p13.3 gain frequently observed in PCa metastases and now demonstrate the prognostic value of this genomic alteration in surgically treated PCa. Dual-color fluorescence in situ hybridization (FISH) was used to detect 16p13.3 gain on a human tissue microarray (TMA) representing 304 primary radical prostatectomy (RP) cases with clinical follow-up data...
October 9, 2017: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28972967/ex-vivo-metabolic-fingerprinting-identifies-biomarkers-predictive-of-prostate-cancer-recurrence-following-radical-prostatectomy
#18
Peder R Braadland, Guro Giskeødegård, Elise Sandsmark, Helena Bertilsson, Leslie R Euceda, Ailin F Hansen, Ingrid J Guldvik, Kirsten M Selnæs, Helene H Grytli, Betina Katz, Aud Svindland, Tone F Bathen, Lars M Eri, Ståle Nygård, Viktor Berge, Kristin A Taskén, May-Britt Tessem
BACKGROUND: Robust biomarkers that identify prostate cancer patients with high risk of recurrence will improve personalised cancer care. In this study, we investigated whether tissue metabolites detectable by high-resolution magic angle spinning magnetic resonance spectroscopy (HR-MAS MRS) were associated with recurrence following radical prostatectomy. METHODS: We performed a retrospective ex vivo study using HR-MAS MRS on tissue samples from 110 radical prostatectomy specimens obtained from three different Norwegian cohorts collected between 2002 and 2010...
October 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28948139/the-role-of-biomarkers-in-the-management-of-bone-homing-malignancies
#19
REVIEW
Stella D'Oronzo, Janet Brown, Robert Coleman
Bone represents a common site of metastasis from several solid tumours, including breast, prostate and lung malignancies. The onset of bone metastases (BM) is associated not only with serious skeletal complications, but also shortened overall survival, owing to the lack of curative treatment options for late-stage cancer. Despite the diagnostic advances, BM detection often occurs in the symptomatic stage, underlining the need for novel strategies aimed at the early identification of high-risk patients. To this purpose, both bone turnover and tumour-derived markers are being investigated for their potential diagnostic, prognostic and predictive roles...
November 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28929505/high-level-glyoxalase-1-glo1-expression-is-linked-to-poor-prognosis-in-prostate-cancer
#20
Christoph Burdelski, Rami Shihada, Andrea Hinsch, Alexander Angerer, Cosima Göbel, Emily Friedrich, Claudia Hube-Magg, Susanne Burdak-Rothkamm, Martina Kluth, Ronald Simon, Christina Möller-Koop, Guido Sauter, Franzika Büscheck, Corinna Wittmer, Till S Clauditz, Till Krech, Maria C Tsourlakis, Sarah Minner, Markus Graefen, Thorsten Schlomm, Waldemar Wilczak, Frank Jacobsen
BACKGROUND: Glyoxalase 1 (GLO1) is an enzyme involved in removal of toxic byproducts accumulating during glycolysis from the cell. GLO1 is up regulated in many cancer types but its role in prostate cancer is largely unknown. METHODS: Here, we employed GLO1 immunohistochemistry on a tissue microarray including 11 152 tumors and an attached clinical and molecular database. RESULTS: Normal prostate epithelium was negative for GLO1, whereas 2059 (27...
November 2017: Prostate
keyword
keyword
98461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"